The SFC has instructed HKEX under Rule 8(1) of the Securities and Futures (Stock Market Listing) Rules to suspend trading in Bokang Shiyun Pharmaceutical-B (02592.HK) from 09:00 on Sept 10, 2026. The regulator said it is seriously concerned the company’s IPO may have been artificially manipulated to create false demand and considers the suspension necessary while it investigates to preserve an orderly, fair market and protect investors. The investigation is ongoing and the SFC will not comment f

State Administration of Foreign Exchange deputy director and spokesman Li Bin said on Sept. 10 at a State Council Information Office briefing that direct investment under China’s capital account has achieved basic convertibility. He said cross-border securities investment has coalesced into an institutional arrangement centered on an institutional investor framework, mutual-access mechanisms and direct market access for overseas investors, and that cross-border financing is subject to comprehensive, all-flow macroprudential oversight.

Semafor reports a US AI safety bill could be submitted as early as next week.